南方医科大学学报2011，Vol.31Issue(5)：854-855,863,3.
CD133在骨髓增生异常综合征患者中的表达及临床意义
Expression of CD133 in the bone marrow of patients with myelodysplastic syndrome and its clinical significance
摘要
Abstract
Objective To investigate the expression of CD133 in the bone marrow of patients with myelodysplastic syndrome (MDS) and explore its clinical significance. Methods The expression of CD133 and CD34/CD38 in the bone marrow was detected using flow cytometry in 31 cases of refractory anemia with excess blasts (RAEB), 10 cases of refractory cytopenia with multilineage dysplasia (RCMD) and 11 cases of aplastic anemia (AA). Results The percentage of CD133-expressing cells was 6.75% in patients with RAEB, significantly higher than that in patients with RCMD (1.41%) and AA (2.70%) (P<0.05); the percentage of CD133-positive cells were similar between the latter two patient groups (P>0.05). The percentage of CD34+/CD38- cells was similar in the 3 groups (P>0.05), all lower than 1%. Conclusions Advanced MDS patients are characterized by an increase of CD133-expressing cells, suggesting the value of CD133 in the diagnosis of RAEB. CD34+/CD38- cells do not show a significant value in the diagnosis of MDS.关键词
骨髓增生异常综合征/CD133/流式细胞术Key words
myelodysplastic syndromes/CD133/flow cytometry分类
医药卫生引用本文复制引用
钟立业,杜欣,耿素霞,翁建宇,郑海涛,吴穗晶,李扬秋..CD133在骨髓增生异常综合征患者中的表达及临床意义[J].南方医科大学学报,2011,31(5):854-855,863,3.基金项目
十一五国家科技支撑计划项目(2008BAI61B02) （2008BAI61B02）
中央高校基本科研业务专项资金(21610603) （21610603）
